Steven H Itzkowitz, MD
img_Steven H Itzkowitz
PROFESSOR | Medicine, Gastroenterology
PROFESSOR | Oncological Sciences
PROFESSOR | Medical Education
Are you a patient?
Gastroenterology, Internal Medicine
Research Topics
Aerodigestive Tract, Cancer, Epithelial Cells, Inflammatory Bowel Disease (IBD)
Multi-Disciplinary Training Area
Cancer Biology [CAB]
Cancer Risk in Patients with Inflammatory Bowel Disease
Many patients with inflammatory bowel disease (IBD) take medicines that affect their immune system. Most of these drugs were initially tested in patients with IBD who did not have a past history of cancer for fear that these agents might promote a recurrence or development of a new cancer. But a recent study by Dr. Itzkowitz and coworkers indicates that even in those patients with IBD who have a history of cancer, taking immune modulating medicines did not predispose them to a recurrence of their cancer or the development of a new cancer. Dr. Itzkowitz is now heading a multicenter registry to follow patients with IBD who have a history of cancer to track their rates of new or recurrent cancer in a prospective fashion.
Reducing disparities in screening colonoscopy
Dr. Itzkowitz helped spearhead community outreach efforts to enhance awareness of colon cancer in East Harlem. He and his colleagues have demonstrated the effectiveness of new strategies to improve the completion rates of screening colonoscopy among minority individuals by employing patient navigators within an open access referral system. This model has now been accepted by most medical centers and ambulatory clinics. 
Mechanisms of inflammation-associated carcinogenesis
Laboratory investigation is exploring the profile of intestinal microbiota in patients with inflammatory bowel disease (IBD) who have primary sclerosing cholangitis - conditions that predispose to colon cancer.

Developing non-invasive colon cancer screening tests
Dr. Itzkowitz's team was part of a national study that demonstrated the utility of stool DNA testing for detecting colon cancer and precancerous polyps in the general population. He is now leading a national study that is testing a modified version of the stool DNA test in patients with IBD who are at increased risk for developing colorectal cancer.

Progression of Neoplasia in Inflammatory Bowel Disease
Studies at Mount Sinai are examining clinical and pathological risk factors to help better understand the factors that promote progression from inflammation to precancerous and cancerous lesions in the colon in patients with IBD. Dr. Itzkowitz is the PI on a new registry that will follow patients with IBD and a past history of cancer who are treated with immune modulating medicines for their IBD, in order to determine whether these medications are associated with the development of recurrent or new cancers. 

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, NYU Hospitals Center

Residency, Internal Medicine, NYU Hospitals Center

Fellowship, Gastroenterology, University of CA at San Francisco School of Medicine


American Board of Internal Medicine


Excellence in Teaching Award

Institute for Medical Education; Mount Sinai School of Medicine


Patient Advocacy Award

East Harlem Health Outreach Project (EHHOP)


Faculty Award

Arnold P. Gold Foundation for Humanism


Academic Achievement Award (Senior Faculty)

Faculty Council, Mount Sinai School of Medicine


Faculty Award

Alpha Omega Alpha Medical Honor Society, Mount Sinai School of Medicine


Best Doctors

Castle Connolly and New York Magazine


Selected Publications

Author Correction: A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma (Nature Communications, (2022), 13, 1, (6041), 10.1038/s41467-022-33377-8). Royce W. Zhou, Jia Xu, Tiphaine C. Martin, Alexis L. Zachem, John He, Sait Ozturk, Deniz Demircioglu, Ankita Bansal, Andrew P. Trotta, Bruno Giotti, Berkley Gryder, Yao Shen, Xuewei Wu, Saul Carcamo, Kaitlyn Bosch, Benjamin Hopkins, Alexander Tsankov, Randolph Steinhagen, Drew R. Jones, John Asara, Jerry E. Chipuk, Rachel Brody, Steven Itzkowitz, Iok In Christine Chio, Dan Hasson, Emily Bernstein, Ramon E. Parsons. Nature Communications

Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Dustin G. Shaw, Raúl Aguirre-Gamboa, Marcos C. Vieira, Saideep Gona, Nicholas DiNardi, Anni Wang, Anne Dumaine, Jody Gelderloos-Arends, Zachary M. Earley, Katherine R. Meckel, Cezary Ciszewski, Anabella Castillo, Kelly Monroe, Joana Torres, Shailja C. Shah, Jean Frédéric Colombel, Steven Itzkowitz, Rodney Newberry, Russell D. Cohen, David T. Rubin, Christopher Quince, Sarah Cobey, Iris H. Jonkers, Christopher R. Weber, Joel Pekow, Patrick C. Wilson, Luis B. Barreiro, Bana Jabri. Nature Medicine

Endoscopic management of patients with high-risk colorectal colitis–associated neoplasia: a Delphi study. Michiel T.J. Bak, Eduardo Albéniz, James E. East, Nayantara Coelho-Prabhu, Noriko Suzuki, Yutaka Saito, Takayuki Matsumoto, Rupa Banerjee, Michal F. Kaminski, Ralf Kiesslich, Emmanuel Coron, Annemarie C. de Vries, C. Janneke van der Woude, Raf Bisschops, Ailsa L. Hart, Steven H. Itzkowitz, Mathieu Pioche, Leon M.G. Moons, Bas Oldenburg. Gastrointestinal Endoscopy

View All Publications

Babyatsky Lecture 2017

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Itzkowitz during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • EXACT Sciences Corporation
  • Geneoscopy

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose

  • New York College of Podiatric Medicine (NYCPM)

Royalty Payments:

  • Bio-Rad Laboratories, Inc.
  • BioRad

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.